Literature DB >> 3741730

The psychopharmacological and electrophysiological effects of single doses of caffeine in healthy human subjects.

M Bruce, N Scott, M Lader, V Marks.   

Abstract

The effects of single doses of anhydrous caffeine (250 mg and 500 mg) and placebo on physiological, psychological measures and subjective feelings were studied in a double-blind, cross-over study in nine healthy subjects who had abstained from caffeine-containing beverages for 24 h before each occasion. Caffeine and caffeine metabolites in plasma and urine were assayed. Peak plasma concentrations were observed at 1 to 2 h with an approximate half-life of 5 h. The concentrations of the metabolite 1,7-dimethylxanthine increased during the 5 h. The major urine metabolite was 1-methyluric acid. The EEG showed a dose-related decrease in log 'theta' power and a decrease in log 'alpha' power. Other dose-related effects were an increase in skin conductance level (sweat-gland activity) and self rating of alertness. Ratings of headache and tiredness were decreased by the caffeine. The study illustrates the complexities of studying a drug which is widely taken and which is often associated with withdrawal effects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3741730      PMCID: PMC1401080          DOI: 10.1111/j.1365-2125.1986.tb02883.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  Enhancement of human performance by caffeine and the amphetamines.

Authors:  B WEISS; V G LATIES
Journal:  Pharmacol Rev       Date:  1962-03       Impact factor: 25.468

2.  Determination of the urinary metabolites of caffeine and theophylline by high-performance liquid chromatography. A comparative study of a direct injection and an ion-pair extraction procedure.

Authors:  N R Scott; J Chakraborty; V Marks
Journal:  J Chromatogr       Date:  1986-03-07

Review 3.  Caffeine.

Authors:  P B Dews
Journal:  Annu Rev Nutr       Date:  1982       Impact factor: 11.848

Review 4.  Caffeine: implications of recent research for clinical practice.

Authors:  Susan J Wells
Journal:  Am J Orthopsychiatry       Date:  1984-07

5.  Neuroendocrine effects of caffeine in normal subjects.

Authors:  E R Spindel; R J Wurtman; A McCall; D B Carr; L Conlay; L Griffith; M A Arnold
Journal:  Clin Pharmacol Ther       Date:  1984-09       Impact factor: 6.875

6.  Caffeine metabolism and coffee-attributed sleep disturbances.

Authors:  M Levy; E Zylber-Katz
Journal:  Clin Pharmacol Ther       Date:  1983-06       Impact factor: 6.875

7.  Determination of caffeine, theophylline and theobromine in serum and saliva using high-performance liquid chromatography.

Authors:  N R Scott; J Chakraborty; V Marks
Journal:  Ann Clin Biochem       Date:  1984-03       Impact factor: 2.057

8.  The psychopharmacological effects of premazepam, diazepam and placebo in healthy human subjects.

Authors:  S Golombok; M Lader
Journal:  Br J Clin Pharmacol       Date:  1984-08       Impact factor: 4.335

9.  Variability of caffeine metabolism in humans.

Authors:  W Kalow
Journal:  Arzneimittelforschung       Date:  1985

10.  Relationship between caffeine concentrations in plasma and saliva.

Authors:  E Zylber-Katz; L Granit; M Levy
Journal:  Clin Pharmacol Ther       Date:  1984-07       Impact factor: 6.875

View more
  25 in total

Review 1.  A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features.

Authors:  Laura M Juliano; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2004-09-21       Impact factor: 4.530

2.  Differential responsiveness to caffeine and perceived effects of caffeine in moderate and high regular caffeine consumers.

Authors:  A S Attwood; S Higgs; P Terry
Journal:  Psychopharmacology (Berl)       Date:  2006-11-29       Impact factor: 4.530

3.  Effects of single and repeated doses of theophylline on aspects of performance, electrophysiology and subjective assessments in healthy human subjects.

Authors:  P Bartel; R Delport; B Lotz; J Ubbink; P Becker
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

4.  Separate and combined effects of the social drugs on psychomotor performance.

Authors:  J S Kerr; N Sherwood; I Hindmarch
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

5.  A comparison of the CNS effects of enprofylline and theophylline in healthy subjects assessed by performance testing and subjective measures.

Authors:  B Tiplady; D Fagan; M Lamont; M Brockway; D B Scott
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

6.  A comparison of the central nervous system effects of caffeine and theophylline in elderly subjects.

Authors:  G Yu; V Maskray; S H Jackson; C G Swift; B Tiplady
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

7.  A specific role for the thalamus in mediating the interaction of attention and arousal in humans.

Authors:  C M Portas; G Rees; A M Howseman; O Josephs; R Turner; C D Frith
Journal:  J Neurosci       Date:  1998-11-01       Impact factor: 6.167

Review 8.  Novel insights on caffeine supplementation, CYP1A2 genotype, physiological responses and exercise performance.

Authors:  Gabriel Barreto; Beatriz Grecco; Pietro Merola; Caio Eduardo Gonçalves Reis; Bruno Gualano; Bryan Saunders
Journal:  Eur J Appl Physiol       Date:  2021-01-05       Impact factor: 3.078

9.  Reinforcing and subjective effects of caffeine in normal human volunteers.

Authors:  K N Stern; L D Chait; C E Johanson
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

10.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.